|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Medi_Gene_AG
gptkb:Mitsubishi_Tanabe_Pharma
|
|
gptkbp:advertising
|
gptkb:Yoshihiro_Matsumoto
|
|
gptkbp:annual_report
|
published
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:born_in
|
gptkb:Japan
|
|
gptkbp:ceo
|
gptkb:Haruo_Naito
|
|
gptkbp:clinical_trial
|
gptkb:Japan
ongoing
extensive
conducts numerous clinical trials
conducts clinical research globally
|
|
gptkbp:collaboration
|
academic institutions
Alzheimer's research
|
|
gptkbp:collaborations
|
collaborates with various research institutions
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._John_Smith
gptkb:Mitsuo_Sato
|
|
gptkbp:employees
|
over 10,000
|
|
gptkbp:focus_area
|
gptkb:cancer_treatment
|
|
gptkbp:founded
|
1941
|
|
gptkbp:founder
|
gptkb:Haruo_Naito
Toyokuni Hoshino
|
|
gptkbp:global_presence
|
over 30 countries
operates in over 70 countries
|
|
gptkbp:headcount
|
approximately 10,000 employees
|
|
gptkbp:headquarters
|
gptkb:Tokyo
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eisai
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:instruction_set
|
has a robust clinical pipeline
|
|
gptkbp:invention
|
over 1,000
numerous
|
|
gptkbp:investment
|
invests in innovative technologies
R& D investments
|
|
gptkbp:market
|
global
global pharmaceutical market
|
|
gptkbp:market_cap
|
approximately $10 billion
|
|
gptkbp:partnership
|
gptkb:Merck
gptkb:Sagent_Pharmaceuticals
gptkb:GSK
gptkb:Johnson_&_Johnson
gptkb:Aurobindo_Pharma
gptkb:Takeda_Pharmaceutical_Company
gptkb:Mylan
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Acel_Rx_Pharmaceuticals
gptkb:Alvogen
gptkb:Catalent
gptkb:Fresenius_Kabi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Teva_Pharmaceuticals
gptkb:Biogen
gptkb:Horizon_Therapeutics
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Intas_Pharmaceuticals
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Sandoz
gptkb:Hikma_Pharmaceuticals
gptkb:Eli_Lilly_and_Company
gptkb:Purdue_Pharma
gptkb:Vertex_Pharmaceuticals
gptkb:Lupin_Pharmaceuticals
gptkb:Sun_Pharmaceutical_Industries
gptkb:Abb_Vie
gptkb:Celgene
gptkb:Novartis
gptkb:Zydus_Cadila
gptkb:Dr._Reddy's_Laboratories
partnership with Biogen
|
|
gptkbp:partnerships
|
gptkb:Amgen
|
|
gptkbp:philanthropy
|
gptkb:Eisai_Foundation
engages in various philanthropic activities
|
|
gptkbp:products
|
gptkb:Lacosamide
medications
Donepezil
anti-cancer drugs
|
|
gptkbp:regulatory_compliance
|
receives regulatory approvals for drugs
|
|
gptkbp:related_products
|
gptkb:Aricept
gptkb:Halaven
gptkb:Lenvatinib
gptkb:Aducanumab
|
|
gptkbp:research_and_development
|
$1 billion (2020)
invests heavily in R& D
|
|
gptkbp:research_areas
|
metabolic disorders
neurology
oncology
focuses on oncology and neurology
|
|
gptkbp:research_focus
|
neurology
|
|
gptkbp:revenue
|
$5.5 billion (2020)
$4.5 billion (2020)
|
|
gptkbp:social_responsibility
|
gptkb:healthcare_access
community engagement
environmental sustainability
|
|
gptkbp:stock_exchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:subsidiaries
|
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:subsidiary
|
gptkb:Eisai_Inc.
|
|
gptkbp:sustainability
|
committed to sustainability initiatives
|
|
gptkbp:website
|
www.eisai.com
|
|
gptkbp:bfsParent
|
gptkb:Biogen
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
4
|